Drug Trial Radar · NCT05792917
Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers
Last checked: Nov 19, 2026Latest source record: Sep 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
166
Actual
Start
Mar 6, 2023
Primary completion
Mar 26, 2023
Study completion Aug 4, 2023
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 31, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This trial is conducted in China. The purpose of this study is to evaluate the pharmacokinetic similarity of Tafolecimab with different manufacturing process in healthy male subjects. Another purpose is to determine safety, and immunogenicity of sintilimab with different manufacturing process,also to determine Pharmacodynamics of Tafolecimab with different manufacturing process
Conditions
- Healthy Male Subjects
Interventions
tafolecimab (a modified manufacturing process)Drug
450mg,SC,single dose
tafolecimab (a original manufacturing process)Drug
450mg,SC,single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Bioequivalence results using the peak serum drug concentration (Cmax) as the judging indicatorsTime frame: up to Day 57
- Bioequivalence results using the area under the serum concentration-time curve (AUC0-inf) as the judging indicatorsTime frame: up to Day 57
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Aerospace Center Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.